Jump to content

Pfizer trial for NSCLC drug halted!


Recommended Posts

Pfizer Halts Enrollment in Cancer-Drug Trial

* Article

* Comments (6)

more in Business »


Pfizer Inc. temporarily halted enrollment of new patients in a clinical trial of an experimental lung-cancer drug, saying the drug was associated with a higher rate of adverse events, including fatalities, than for patients who didn't get the drug.

The drug, figitumumab, was in a Phase III, or late-stage, trial in patients with a form of the disease known as nonadenocarcinoma, nonsmall-cell lung cancer.

The trial began around March of last year and was projected to have about 820 patients before ending in 2011, according to a U.S. government clinical-trial database. Some of the patients were given figitumumab, also known ...

Link to comment
Share on other sites

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.

Reply to this topic...

×   Pasted as rich text.   Restore formatting

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

  • Create New...

Important Information

By using this site, you agree to our Terms of Use. We have placed cookies on your device to help make this website better. You can adjust your cookie settings, otherwise we'll assume you're okay to continue.